Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Invested Capital (2021 - 2025)

UroGen Pharma's Return on Invested Capital history spans 5 years, with the latest figure at 0.74% for Q4 2025.

  • For Q4 2025, Return on Invested Capital rose 1258.0% year-over-year to 0.74%; the TTM value through Dec 2025 reached 0.74%, up 1258.0%, while the annual FY2025 figure was 6.58%, 926.0% down from the prior year.
  • Return on Invested Capital reached 0.74% in Q4 2025 per URGN's latest filing, down from 1.3% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 20.68% in Q1 2022 to a low of 11.85% in Q4 2024.
  • Average Return on Invested Capital over 5 years is 1.57%, with a median of 0.74% recorded in 2025.
  • Peak YoY movement for Return on Invested Capital: crashed -2043bps in 2023, then skyrocketed 1664bps in 2024.
  • A 5-year view of Return on Invested Capital shows it stood at 4.68% in 2021, then skyrocketed by 107bps to 0.33% in 2022, then surged by 284bps to 1.27% in 2023, then tumbled by -1032bps to 11.85% in 2024, then skyrocketed by 106bps to 0.74% in 2025.
  • Per Business Quant, the three most recent readings for URGN's Return on Invested Capital are 0.74% (Q4 2025), 1.3% (Q3 2025), and 1.82% (Q2 2025).